Alpha Tau Medical

DRTS

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$2.8m

Combined value at quarter end

Last quarter

1 bought

0 sold or trimmed

Price at Q2 ’26 end

$12.58

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

0Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Alpha Tau Medical.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Alpha Tau Medical

Polen Capital Management	0.0%$2.8m	$2.8m	New	1 qtr

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Alpha Tau Medical
		Bought or sold				Filing
21 Aug 2026	Levy RaphiChief Financial Officer	▼ Sold	2,871	$15.00	$43k	Form 4
11 Aug 2026	Levy RaphiChief Financial Officer	▼ Sold	17,730	$14.00	$248k	Form 4

About the company

Sector: Health care · Surgical & Medical Instruments & Apparatus
Financial year ends: 31 December
Shares outstanding: 88m at 31 Dec 2025
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

Alpha Tau Medical revenue and net income by year
Year	Revenue	Net income
2025	–	−$42.6m
2024	–	−$31.8m
2023	–	−$29.2m
2022	–	−$33.8m
2021	–	−$27.3m
2020	–	−$8.9m
2019	–	−$8.4m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.